Palatin Technologies, Inc. ( PTN)

Q4 2010 Earnings Call

February 24, 2011 11:00 am ET

Executives

Carl Spana – President and Chief Executive Officer

Stephen T. Wills – Chief Financial Officer and Executive Vice President – Operations

Presentation

Operator

Good morning, ladies and gentlemen, and welcome to the Palatin Technologies Second Quarter Fiscal Year 2011 Conference Call. All participants are in a listen-only mode.

Due to certain disclosure restrictions surrounding Palatin's announcement this morning of its pricing of a public offering of its common stock and warrants, there will not be a question-and-answer session at the end of the company's remarks. As a reminder, this conference call is being recorded.

Before we begin our remarks, I would you like to remind you that statements made by Palatin that are not historical facts may be forward-looking statements. These statements are based on assumptions that may or may not prove to be accurate and actual results could differ materially from those anticipated due to a variety of risks and uncertainties discussed in the company's most recent filings with the Securities and Exchange Commission. Please consider such risks and uncertainties carefully in evaluating these forward-looking statements and Palatin's prospects.

Now, I would like to introduce your host for today's call, Dr. Carl Spana, President and Chief Executive Officer of Palatin Technologies. Go ahead, sir.

Carl Spana

Thank you. Good morning. I'm Carl Spana, President and CEO of Palatin Technologies. With me on the phone today is Steve Wills, our Executive Vice President of Operations and Chief Financial Officer, and Dr. Jeffrey Edelson, our Chief Medical Officer.

If you liked this article you might like

How to Trade Today's Most Active Stocks -- Ford, Palatin, More

Palatin Female Libido-Boosting Shot Fails Crucial Sex Frequency Test

Insider Trading Alert - AEL, PTN And BSX Traded By Insiders

Palatin Technologies (PTN) Stock Up After FDA Approval of 'Female Viagra'

Palatin Technologies (PTN) Stock Climbing on FDA Approval of 'Female Viagra'